WAVEMAN · COMPANY

TKNO · Alpha Teknova, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

TKNO

Name: Alpha Teknova, Inc. (TKNO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Alpha Teknova, Inc.

PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0001850902

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+7.4%

XBRL, annual

NET MARGIN

-42.6%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

49 funds added or opened last quarter

below 56% of Pharma & Biotech

REVENUE

+7.4% year over year

more than 57% of Pharma & Biotech

MARGIN

-42.6% net margin

below 57% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

49 funds added or opened positions in the latest 13F quarter, of 82 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +75.7%

+75.7%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 49 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Alpha Teknova, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Lowell Matthew

Chief Financial Officer

BUY

2026-03-06

40,000.0

$87.6K

Gunstream Stephen

President and CEO

BUY

2026-03-06

26,000.0

$55.9K

DEMSKI MARTHA J

Director

SELL

2025-06-27

8,000.0

$40.5K

Telegraph Hill Partners IV, L.P.

—

BUY

2024-07-12

11,126,929.0

$13.8M

Telegraph Hill Partners IV, L.P.

—

BUY

2024-07-12

969,844.0

$1.2M

39 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 34 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

ROYCE & ASSOCIATES LP

1,661,395.0 sh

$9.4M

VANGUARD CAPITAL MANAGEMENT LLC

1,614,045.0 sh

$9.2M

Roubaix Capital, LLC

1,579,404.0 sh

$9.0M

BlackRock, Inc.

879,786.0 sh

$5.0M

UBS Group AG

631,967.0 sh

$3.6M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Royce Capital Fund - Micro-Cap Portfolio

$286.2K POSITION · AS OF 2026-03-31

0.3%

Royce Micro-Cap Fund

$890.3K POSITION · AS OF 2026-03-31

0.3%

Ultra-Small Company Market Fund

$144.5K POSITION · AS OF 2026-03-31

0.1%

Goldman Sachs Small Cap Growth Insights Fund

$90.0K POSITION · AS OF 2026-04-30

0.0%

Venerable US Small Cap Fund

$21.8K POSITION · AS OF 2026-03-31

0.0%

Invesco Nasdaq Biotechnology ETF

$7.7K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$40.5M	$37.7M	$36.7M	$41.4M
GROSS PROFIT	$13.4M	$7.2M	$10.3M	$17.5M
OPERATING INCOME	$-17.0M	$-26.1M	$-35.6M	$-49.7M
NET INCOME	$-17.3M	$-26.7M	$-36.8M	$-47.5M
EPS (DILUTED)	-0.32	-0.57	-1.16	-1.69
OPERATING CASH FLOW	$-8.6M	$-12.4M	$-18.8M	$-27.4M
CASH	$5.9M	$3.7M	$28.5M	$42.2M
LONG-TERM DEBT	$13.1M	$9.4M	$13.3M	$22.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE